Pfizer (NYSE:PFE) Trading Up 0.4%

Pfizer Inc. (NYSE:PFE - Get Free Report) shot up 0.4% during mid-day trading on Thursday . The stock traded as high as $27.93 and last traded at $27.89. 7,034,138 shares were traded during trading, a decline of 84% from the average session volume of 43,280,914 shares. The stock had previously closed at $27.78.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PFE. Truist Financial dropped their price objective on shares of Pfizer from $42.00 to $36.00 and set a "buy" rating for the company in a research note on Thursday, December 14th. TD Cowen cut shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Argus cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research note on Friday, March 1st. Finally, UBS Group dropped their price target on shares of Pfizer from $34.00 to $27.00 and set a "neutral" rating for the company in a research note on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $36.88.

Pfizer Price Performance

The stock's fifty day moving average price is $27.46 and its two-hundred day moving average price is $29.46. The firm has a market capitalization of $157.14 billion, a price-to-earnings ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the business earned $1.14 EPS. The company's revenue was down 41.3% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently made changes to their positions in the company. Worth Asset Management LLC acquired a new stake in shares of Pfizer in the first quarter valued at about $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the third quarter worth about $30,000. Main Street Group LTD purchased a new stake in Pfizer in the fourth quarter valued at approximately $30,000. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 811 shares during the period. Finally, Creekmur Asset Management LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.